Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

Table 1 Endomyocardial biopsy scores of patients treated with high cumulative doses of pegylated liposomal doxorubicin

Patient	Age	Sex	Underlying disease	Prior doxorubicin dose (mg/m²)	Cumulative PLD dose (mg/m²)	Billingham score	Reference
1	Unknown	M	KS	0	500	1	[25]
2	Unknown	M	KS	0	541	0	[25]
3	35	F	Breast cancer^a	180	564	0.5	[26]
4	Unknown	M	KS	0	578	0	[25]
5	Unknown	M	KS	0	610	0.5	[25]
6	54	F	Breast cancer^a	0	675	0.5	[27]
7	47	F	Breast cancer^a	0	685	0	[26]
8	66	F	Ovarian cancer	0	730	0	[26]
9	Unknown	M	KS	0	780	0	[25]
10	Unknown	M	KS	0	801	0.5	[25]
11	Unknown	M	KS	0	860	0	[25]
12	36	F	Ovarian cancer	375	952	0	[26]
13	52	F	Breast cancer^a	360	1320	1.5	[26]
14	49	F	Breast cancer	0	1485	1	[26]

Abbreviations: M Male, F Female, KS Kaposi sarcoma, PLD Pegylated liposomal doxorubicin
^aPatients 3, 6, 7, and 13 received prior radiotherapy to the breast

ISSN: 1471-2334